Yes NP also claims in recent IV that BP was unable
Post# of 145699
I believe the other point of disagreement leading to the cooling of the relationship is that BP wanted to exclude mild Covid patients who didn't have elevated immunological biomarkers (i.e. RANTES) from the CD10 trial. Obviously they were let in, perhaps diluting the strength of the trial results. Perhaps results were still good enough to get approval. Will see what UK MHRA and FDA say.